Leveraging an Energy Expenditure Mechanism to Drive Liver-Targeted Reductions in Fat and Inflammation, the Primary Drivers of MASH
- Leveraging a mitochondrial uncoupling approach to increase resting energy expenditure, resulting in muscle-preserving reductions in fat, particularly visceral fat, while independently reducing inflammation.
- Utilizing a liver-targeted therapy to reduce liver fat and inflammation, the primary drivers of MASH, while preserving muscle, which is critical for sustained cardiometabolic health.
- Developing oral small molecule therapies with favorable tolerability profiles to address chronic metabolic dysfunction, improving long-term patient management, and supporting sustained cardiometabolic health.